R315
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 68
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- MTORC1_SIGNALING+0.410
- ANDROGEN_RESPONSE+0.400
- MYC_TARGETS_V1+0.390
- G2M_CHECKPOINT+0.370
- MITOTIC_SPINDLE+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.360
- PI3K_AKT_MTOR_SIGNALING+0.340
- CHOLESTEROL_HOMEOSTASIS+0.320
- TGF_BETA_SIGNALING+0.320
Top 10 suppressed
- ANGIOGENESIS-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- COAGULATION-0.220
- KRAS_SIGNALING_DN-0.210
- MYOGENESIS-0.160
- PANCREAS_BETA_CELLS-0.150
- XENOBIOTIC_METABOLISM-0.150
- ESTROGEN_RESPONSE_LATE-0.130
- HEDGEHOG_SIGNALING-0.130
- APICAL_JUNCTION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d5610bbc-93c5-4ca5-b687-f955d1b84c92 | — | — | 0.858 |
| 2 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.845 |
| 3 | SRR8942952 | — | — | 0.842 |
| 4 | C9523C23-CF9B-4C33-A256-4106AD46729D | — | — | 0.842 |
| 5 | 33060001-05C9-4751-AA58-F194207ACC08 | — | — | 0.841 |
| 6 | SRR934851 | — | — | 0.837 |
| 7 | C4A69C6F-E199-43CF-9DA1-94E1B3AE7388 | — | — | 0.832 |
| 8 | c353cc16-2e98-48ac-8416-49f1532466f7 | — | — | 0.823 |
| 9 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.823 |
| 10 | SRR934930 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |